A perpetual platform trial in every major cancer, funded as infrastructure
Instead of starting a new trial for every drug pair, keep one always-open trial per cancer that new arms can join and leave, sharing the same control group.
STAMPEDE (prostate) and I-SPY 2 (breast) showed that a standing master protocol with a shared control arm can test many treatments for a fraction of the cost and time of separate trials. Yet most common cancers still have no perpetual platform. The proposal is a ten-year, ring-fenced infrastructure grant per tumour type (lung, colorectal, pancreas, ovary, bladder, glioma, myeloma and others) so that the platform outlives any single sponsor or investigator.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
Pages like this
not linked directly; found by shared links- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost, Glioma & glioblastoma.
- IdeaShared concurrent control arms across sponsors' trials in the same setting
Shares Basket, umbrella, and platform trials, Too many combinations to test, Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost, Glioma & glioblastoma.
- IdeaPublish per-patient trial cost benchmarks and target halving them
Shares Cancer Research UK, National Cancer Institute (NIH), Trial design, endpoints and cost.
- IdeaA RECOVERY-style permanent platform trial of cheap drugs added to cancer care
Shares Basket, umbrella, and platform trials, Cancer Research UK, Trial design, endpoints and cost.
- IdeaAdd a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial
Shares Cancer Research UK, National Cancer Institute (NIH), Trial design, endpoints and cost.
- IdeaCompeting sponsors share one control arm in the same indication
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost, Pancreatic ductal adenocarcinoma.
- IdeaLet the trial learn: response-adaptive allocation across many combination arms
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost.